TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2565728
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg WY-45,727
Study: 2565728
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg WY-45,727
Study: 28188086
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group A (150 mg oral vismodegib per day for 12 weeks, then three rounds of 8 weeks of placebo daily followed by 12 weeks of 150 mg vismodegib daily)
Study: 28188086
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group B (150 mg oral vismodegib per day for 24 weeks, then three rounds of 8 weeks of placebo daily followed by 8 weeks of 150 mg vismodegib daily)
Study: 28188086
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group A
Study: 28188086
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group B
Study: 25068884
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (COL; 1.7 g·kg(‐1)·day(‐1) for 7 days)
Study: 15510897
Drug: Alprazolam 3
Normalized name: alprazolam 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 3 x 0.5 mg
Study: 15510897
Drug: Diazepam 3
Normalized name: diazepam 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 3 x 2 mg
Study: 11479694
Drug: Cyfra 21-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyfra 21-1 levels after treatment in NSCLC patients
Study: 8303945
Drug: Lederle/Takeda acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lederle/Takeda acellular pertussis component diphtheria‐tetanus‐pertussis vaccine (APDT)
Study: 8303945
Drug: Lederle whole‐cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lederle whole‐cell pertussis component diphtheria‐tetanus‐pertussis vaccine (DTP)
Study: 2498507
Drug: Intralesional recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional recombinant tumor necrosis factor-alpha (rTNF) at a recommended dose of 25 micrograms/m2
Study: 30296436
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (controls, n = 206)
Study: 27761981
Drug: Dialysate bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate bicarbonate of 34 mmol/L
Study: 27761981
Drug: Dialysate bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate bicarbonate of 30 mmol/L
Study: 24456438
Drug: Prophylactic single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic single-dose antibiotics
Study: 24456438
Drug: Prolonged course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged course of antibiotics
Study: 22108776
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) during tuberculosis treatment
Study: 22108776
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) off tuberculosis treatment
Study: 22108776
Drug: Slow metabolizers
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow metabolizers with tuberculosis treatment
Study: 22108776
Drug: Slow metabolizers
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow metabolizers without tuberculosis treatment
Study: 22108776
Drug: Overall effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall effect of tuberculosis treatment on EFV clearance
Study: 1911021
Drug: 0.08% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08% bupivacaine 8 ml
Study: 1911021
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline 8 ml
Study: 6811766
Drug: Megavoltage radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megavoltage radiation therapy
Study: 31587995
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg escitalopram/day in addition to structured psychosocial intervention (PSI)
Study: 19846844
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg of nonadjuvanted vaccine
Study: 19846844
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg of vaccine (with or without adjuvant)
Study: 19846844
Drug: Vaccine without
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine without adjuvant
Study: 16907966
Drug: Isoflavone-enriched cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone-enriched cereal bars (50 mg isoflavones/day; genistein to daidzein ratio 2:1)
Study: 4923928
Drug: Amitriptyline 75
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 75 mg/day
Study: 11717605
Drug: COER verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: COER verapamil 180 to 540 mg once daily in the evening for up to 10 weeks
Study: 11717605
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator agent
Study: 9553866
Drug: 0.1% ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ketorolac tromethamine oral rinse, twice daily for 6 months
Study: 7894000
Drug: Intravenous alfacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfacalcidol (4 micrograms, thrice-weekly for 6 weeks)
Study: 7894000
Drug: Oral alfacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alfacalcidol (4 micrograms, thrice-weekly for 6 weeks)
Study: 18259100
Drug: Intravenous alfacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfacalcidol
Study: 7894000
Drug: Oral alfacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alfacalcidol
Study: 26513991
Drug: Chinese traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese traditional treatment after routine treatment
Study: 23884027
Drug: Mud-bath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud-bath therapy (MBT) for more than 10 years (group A)
Study: 23884027
Drug: Mud-bath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud-bath therapy (MBT) for 3 to 10 years (group B)
Study: 19240655
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) - 17beta‐estradiol (1 mg) with cyclic micronized progesterone (200 mg) for 10 days per month
Study: 9403359
Drug: Methylsergide and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylsergide and Propranolol (antagonists at 5-HT receptors)
Study: 9403359
Drug: Ergotamine and
Normalized name: Belladonna alkaloid and ergotamine and phenobarbital only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergotamine and Sumatriptan (5-HT1 agonists)
Study: 28855225
Drug: High fiber
Normalized name: High Fiber Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fiber from supplement (HFS)
Study: 23019940
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard chemotherapy)
Study: 15144931
Drug: Carvedilol (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (maximum dose of 25 mg bid)
Study: 1642222
Drug: Ranitidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine plus enteric‐coated charcoal (four tablets daily)
Study: 1642222
Drug: Ranitidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine plus bismuth (30 ml Pepto‐Bismol four times daily)
Study: 1642222
Drug: Ranitidine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine alone (300 mg at bedtime)
Study: 1642222
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg at bedtime) with all regimens
Study: 6800389
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg orally)
Study: 6138315
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg orally)
Study: 26012788
Drug: Interferential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential therapy (effective stimulation)
Study: 21206386
Drug: GEMOX (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOX (gemcitabine 1,000 mg/m on days 1 and 8 followed by oxaliplatin 130 mg/m on day 1 every 3 weeks)
Study: 21206386
Drug: PCb (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCb (paclitaxel 225 mg/m followed by carboplatin AUC = 6 on day 1 every 3 weeks)
Study: 17466657
Drug: Paroxetine controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine controlled release (12.5-62.5 mg/day)
Study: 15039515
Drug: Acetylcarnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcarnitine (2 g/d)
Study: 15039515
Drug: Propionylcarnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionylcarnitine (2 g/d)
Study: 11478511
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily (group A)
Study: 3479525
Drug: Lecithin treatment
Normalized name: Lecithin
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecithin treatment
Study: 9683394
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil treatment
Study: 7849232
Drug: Cefoperazone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone (1 g administered intravenously over 3-5 min)
Study: 3154472
Drug: T-cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell antibody positive cases
Study: 23631804
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplement (50,000 IU weekly for 8 weeks and 50,000 IU monthly for 10 months)
Study: 22151921
Drug: Gluteal intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluteal intramuscular corticosteroid injection
Study: 22151921
Drug: Gluteal intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluteal intramuscular placebo (saline) injection
Study: 19673352
Drug: Cefteram pivoxil
Normalized name: cefteram pivoxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefteram pivoxil (CFTM‐PI) 300 mg, three times daily for three days (Group B)
Study: 19673352
Drug: Cefteram pivoxil
Normalized name: cefteram pivoxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefteram pivoxil (CFTM‐PI) 300 mg, three times daily for five days (Group C)
Study: 19673352
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral antimicrobial administration (Group A)
Study: 10776974
Drug: Tiorfan (racecadotril)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiorfan (racecadotril) 300 mg/day from D0 to D15
Study: 10776974
Drug: Tiorfan (racecadotril)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiorfan (racecadotril) 300 mg/day
Study: 31356535
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) 0.5-µg/kg overload dose for 10 minutes and a 0.5-μg/kg/h maintenance dose
Study: 22281837
Drug: Virtual coach
Normalized name: coachwhip stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual coach intervention (automated, animated computer agent providing personalized feedback and goal setting)
Study: 1983344
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg q.d.s. for 1 week
Study: 1983344
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg nocte for 1 week
Study: 1983344
Drug: Sufotidine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufotidine 300 mg b.d. for 1 week
Study: 1983344
Drug: Sufotidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufotidine 600 mg b.d. for 14 days
Study: 28891826
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.375% ropivacaine
Study: 31820601
Drug: Jingtong granule
Normalized name: BUTYLENE GLYCOL 1.6 g in 8 g CUTANEOUS TAPE [LingLongJiuHuo Linglong Moxibustion]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jingtong granule (4 g, 3 times a day)
Study: 23225093
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and intracameral anesthesia without sedation during first eye surgery
Study: 23225093
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and intracameral anesthesia without sedation during second eye surgery
Study: 21916971
Drug: Single or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or double dose of MF59-adjuvanted influenza A(H1N1) vaccine
Study: 21916971
Drug: Seasonal influenza
Normalized name: seasonal influenza, intradermal, preservative free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal influenza vaccine (virosome-adjuvanted trivalent influenza vaccine)
Study: 21916971
Drug: Pandemic vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic vaccine
Study: 21916971
Drug: Local adverse
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local adverse events at the injection site of pandemic vaccine
Study: 21916971
Drug: Local adverse
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local adverse events at the injection site of seasonal vaccine
Study: 15853098
Drug: saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline solution
Study: 12755970
Drug: Sunscreen cream
Normalized name: GLYCERIN 1 g in 50 g TOPICAL CREAM [SUNSCREEN Cream]
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen cream use
Study: 19309745
Drug: New chemotherapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New chemotherapeutic agents
Study: 16805714
Drug: Biological agents
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological agents
Study: 7984977
Drug: Beta-lactam antibiotics
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam antibiotics for 10 days
Study: 77367
Drug: Oral cromoglycate
Normalized name: cromoglycate
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cromoglycate
Study: 26530268
Drug: Canagliflozin 200
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Canagliflozin 200 mg
Study: 18834673
Drug: Dose-escalated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-escalated radiation and concurrent temozolomide
Study: 15236782
Drug: Probenecid 250
Normalized name: probenecid 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid 250 mg twice daily for seven days
Study: 12049858
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg, starting postoperatively
Study: 12049858
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg, starting preoperatively
Study: 9804592
Drug: Naloxone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.15 mg/kg iv)
Study: 8983937
Drug: Capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation of thiocolchicoside (8 mg)
Study: 8983937
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of thiocolchicoside (8 mg)
Study: 794665
Drug: Hydergin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergin (3 mg daily)
Study: 17110814
Drug: STS 6
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: STS 6 mg/24 h
Study: 15322328
Drug: Alprostadil (PGE(1),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil (PGE(1), Prostavasin, intravenous, infusion rate: 0.38 microg/h/kg)
Study: 11285377
Drug: Prednisolone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 7.5 mg daily over 2 years
Study: 31482684
Drug: Curcumin nanomicelle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin nanomicelle (40 mg, 3 times a day for 12 weeks)
Study: 28187466
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Mangifera indica fruit powder
Study: 28187466
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Mangifera indica fruit powder
Study: 26133902
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM), standardized extract of 7 selected ingredients, 5 capsules twice daily for 8 weeks.
Study: 12540632
Drug: C-Peptide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-Peptide (600 nmol/24 h, four doses s.c.)
Study: 11712303
Drug: Lidocaine administered
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine administered intravenously (single dose over 2 minutes)
Study: 8174496
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g single dose)
Study: 1813733
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g triple dose)
Study: 6181113
Drug: Ragweed allergoid
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed allergoid administered in a clustered regimen
Study: 6181113
Drug: Unaltered ragweed
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unaltered ragweed extract (allergen) in a weekly regimen
Study: 31858126
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (intramuscular injections every 2 weeks for 22 weeks)
Study: 31858126
Drug: Placebo (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intramuscular injections every 2 weeks for 22 weeks)
Study: 21295880
Drug: Accelerated fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated fractionation (AF) - 1.1Gy+2.0Gy/day, 5days/week for 4.5weeks, total dose 68Gy
Study: 21295880
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation (CF) - 2Gy/day, 5days/week for 7 weeks, total dose 68Gy
Study: 14961966
Drug: Ozonated autohemotherapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonated autohemotherapy (O3‐AHT) with ozone concentration of 50 micro g/ml
Study: 3523663
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms terbutaline in one inhalation
Study: 31978126
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) - 30 breaths twice-daily at 50% of maximal inspiratory pressure (MIP) for 8 weeks
Study: 31978126
Drug: Otago Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otago Exercise Program (OEP) - Resistance and mobility exercises for 60 minutes, twice-weekly for 8 weeks
Study: 29419917
Drug: Ertugliflozin 5
Normalized name: ertugliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 5 mg/d
Study: 29419917
Drug: Ertugliflozin 15
Normalized name: ertugliflozin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 15 mg/d
Study: 25341356
Drug: Xuebijing Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing Injection 50 mL Bid
Study: 20360607
Drug: Home-based rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based rehabilitation program (4 physical therapy sessions)
Study: 16002493
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy-supervised rehabilitation program (17 physical therapy sessions)
Study: 12781412
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Tc-99m labelled albumin particles before sterilization
Study: 12781412
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Tc-99m labelled albumin particles after sterilization
Study: 1542501
Drug: Drug intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug intake during pregnancy (excluding pregnancy supplements)
Study: 1542501
Drug: Hormonal support
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal support therapy
Study: 1542501
Drug: Human teratogenic
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human teratogenic drugs
Study: 1542501
Drug: General drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: General drug use during pregnancy
Study: 3890282
Drug: Trimethoprim (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (300 mg twice daily for five days)
Study: 3890282
Drug: Co-trimoxazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (two tablets twice daily for five days)
Study: 27029912
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) (n = 48)
Study: 22805100
Drug: 60 mg/d
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/d oral prednisone for 14 days with a 5‐day taper (121 patients)